Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Bell Potter banks march

Bell Direct
March 11, 2016

Portfolio Strategy Builder

Bell Direct
March 7, 2016

Technical Insights Tutorial

Bell Direct
March 7, 2016

Daily Trading Idea Tutorial

Bell Direct
March 7, 2016

Market Insights 26 Feb

Julia Lee
February 26, 2016

Small Cap CEO Interview: Ahalife

Bell Direct
February 24, 2016

Bell Potter: Hybrid stocks

Bell Direct
January 28, 2016

Bell Potter outlook: resources

Bell Direct
January 26, 2016

Richard Hemming: small cap dividend stocks

Richard Hemming
January 22, 2016

Bell Potter Financials Outlook

Bell Direct
January 22, 2016